All PlansCoverageMedium impact
Cryosurgical Ablation of Miscellaneous Solid Tumors Outside of the Liver
Regence BlueShield·Oncology, Urology, Dermatology +3 more·Medical Policy
Effective date
Jun 1, 2026
We identified it
Jun 16, 2026
Summary
New policy SUR132 establishes coverage criteria for cryosurgical ablation of solid tumors outside the liver, effective June 1, 2026. The policy defines specific medical necessity criteria for various tumor types including dermatologic, kidney, prostate, lung cancer, and others, while considering focal prostate cryoablation and breast tumor cryoablation as investigational.
Action Required
Before June 1, 2026: Billing team must review cryosurgical ablation claims to ensure they meet the specific medical necessity criteria outlined in policy SUR132. Update prior authorization workflows to verify tumor type and location criteria. Providers must submit History and Physical plus treatment plan including treatment area for all cryoablation procedures. Claims not meeting policy criteria may be denied as investigational.